James Halley

The advanced wound care company announced second-quarter earnings.

Biotech is still booming, if you pick the right biotech stocks.

The company reported a net loss but improved revenue in the second quarter.

The company reported declining revenue and reduced annual guidance.

Despite strong financials, the company downgraded yearly guidance.

The company replaced its CEO and reported strong revenue growth.

The company released its second-quarter earnings report.

The company saw revenue decline and net losses rise in the second quarter.

The company saw a slight revenue decline in its fiscal 2023 third-quarter earnings report.

The company released second-quarter earnings, and they were disappointing.

Their finances are improving.

The company said it is receiving financing of up to $150 million dollars from private investors.

The company's shares continued to tumble after it received a Complete Response Letter last week from the FDA.

The company announced it was entering into a merger agreement to be acquired by Nautic Partners and will combine with ExactCare Pharmacy, a portfolio company of Nautic.

Shares of Humana, Vertex Pharmaceuticals, and Idexx Laboratories have all increased by at least 20% so far this year.

The company released second-quarter earnings.

The company received a Complete Response Letter from the FDA regarding its prospective graft-versus-host disease therapy.

The company reported improved financials in the third quarter.

The company got a boost when a competitor's quarterly report showed that macroeconomic factors may also help SmileDirectClub's business.

The drugstore company may be benefiting from a short squeeze.